Driehaus Capital Management
Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies.
Business Model:
Revenue: $4.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Driehaus Capital Management Information
Geographic Data
Address: 25 East Erie Street
City: Chicago
State: IL
Zip: 60611
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$82M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
3,640,526Website Global Rank
3,627Website Monthly Traffic
Twitter Followers
Description
Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies. The firm has a diverse institutional client base comprised of corporate and public pensions, endowments, foundations, sub-advisory, family offices, wealth managers, and financial advisors, globally. Driehaus is a performance-oriented investment management boutique that emphasizes integrity, transparency, and the alignment of the firm’s interests with its clients. The firm was founded in 1982 and is headquartered in Chicago, Illinois.
Contact Phone:
+13125873800
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2020 | Elevation Oncology | Series A | 32.5M |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 12/2019 | ArcherDX | Series C | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 4/2021 | C2i Genomics | Series B | 0 |
| 2/2022 | Congruence Therapeutics | Series A | 0 |
| 7/2019 | Frontier Medicines | Series B | 88.5M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 8/2016 | Trace.com | Seed Round | 895k |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 4/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 75M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 5/2019 | Pulmonx | Series G | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 2/2019 | Peloton Therapeutics | Series E | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 6/2000 | Alloptic | Venture Round | 8M |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 9/2022 | Sonendo | Post-IPO Equity | 63M |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 2/2022 | Congruence Therapeutics | Series A | 0 |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 4/2021 | C2i Genomics | Series B | 0 |
| 4/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
